Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and to the discovery and development of novel therapeutics for autoimmune indications. In July 2010, Momentaâs lead product (developed in collaboration with Sandoz) was approved as the first generic version of LOVENOXÂŽ (Enoxaparin Sodium Injection). In April 2015, the company announced the FDA approval of once daily GlatopaÂŽ 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of COPAXONEÂŽ 20 mg/mL. Glatopa was also developed in collaboration with Sandoz. The company's development pipeline includes a biosimilar version of HUMIRAÂŽ (adalimumab), a biosimilar version of ORENCIAÂŽ (abatacept) and a portfolio of five other early stage biosimilar programs in collaboration with Mylan and three novel drug candidates for autoimmune indications. Source
No articles found.
BioCardia, Inc., headquartered in San Carlos, California, is developing regenerati...
BioCardia, Inc., headquartered in San Carlos, C...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
ProLung is a medical technology company specializing in innovative predictive anal...
ProLung is a medical technology company special...
WinSanTorâs mission is simple-develop a drug that works. We recognize that there...
WinSanTorâs mission is simple-develop a drug ...
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...
Corbus Pharmaceuticals Holdings, Inc. is a Phas...
aTyrâs mission is to translate newly discovered biological pathways to develop i...
aTyrâs mission is to translate newly discover...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.